Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:17:38 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:CYCC from 2023-05-04 to 2024-05-03 - 22 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 16:30U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
2024-04-30 07:00U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2024-04-01 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
2024-03-19 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-03-13 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
2024-03-07 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
2024-03-06 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
2024-02-20 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
2024-01-30 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
2024-01-08 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
2024-01-02 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Present at Biotech Showcase 2024
2023-12-22 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
2023-12-18 09:00U:CYCCNews ReleaseCyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
2023-12-12 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals Announces Reverse Stock Split
2023-11-30 09:15U:CYCCNews ReleaseCyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
2023-11-28 17:15U:CYCCNews ReleaseCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
2023-11-13 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
2023-11-07 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results
2023-08-09 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
2023-08-03 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
2023-05-11 16:05U:CYCCNews ReleaseCyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
2023-05-04 09:15U:CYCCNews ReleaseCyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results